Italfarmaco SpA products

Vasexten (barnidipina) third-generation dihydropyridine calcium channel antagonist holds high efficacy standards, improving the tolerability profile, minimizing the typical side effects of this class (peripheral edemas and reflex tachycardia) thanks to its lipophilic structure and formulation in modified-release capsules (unique for its class). Vasexten allows optimal control of the hypertensive patient both as single-agent therapy and in combination with other antihypertensive drugs. On Vasexten Italfarmaco has obtained different and original experimental data about blood pressure control, organ protection in collaboration with head physicians and primary Italian Specialist Centers.

Coripren is the pre-established combination of Enalapril and Lercanidipine. Coripren uses the synergy between ace-inhibitor and calcium channel antagonist in accordance with the most recent European Guidelines. Besides the superior blood pressure control provided in terms of responders rate, the reduced number of tablets obtained with the combination is a pivotal factor to achieve full treatment adherence, thus maintaining the therapeutic goal.

Dedralen (doxazosina) is an alpha-blocker antihypertensive drug well-established medication in combined treatments requiring an alpha-blocking activity with positive effects, also from the metabolic standpoint.

Natemille in orodispersible tablets with 600 mg and 1,000 IU of Vitamin D3, provides the daily intake of Vitamin D recommended by the major guidelines and the amount of calcium sufficient for patients already taking a certain amount of dietary calcium.

Xarenel provides Vitamin D, when required, in the prevention and treatment of deficiencies. Different formulations, flexible dosing options and a good tolerability profile enable to provide a different treatment option, designed according to the single patient requirements. There are increasing scientific evidence and publications supporting benefit treatments resulting from maintaining optimal vitamin D levels both in patients with bone metabolis disorders and patients with major cardiovascular, neurologic and immune diseases.

Flexen (ketoprofene 50 mg capsules; sustained-release 200 mg capsules; 5% gel 50 g tube; 100 mg suppositories; IV 100 mg solution for injections; 100 mg i.m solution for injections) a complete range of formulations for a targeted choice in inflammatory and painful, acute and chronic conditions of the musculoskeletal system.

Nimedex (nimesulide in ß-cyclodextrin granules of 400 mg for oral suspension) combines the treatment benefits of the active ingredient nimesulide with the pharmacokinetic advantages of ß-cyclodextrin. The innovative formulation of Nimedex facilitates its solubilization, anticipates the absorption of the active ingredient and provides a quicker analgesic effect compared with the other Nimesulide-based preparations. In addition, thanks to a shorter topic permanence of the active ingredient in the gastro-intestinal lumen, Nimedex provides a better local tolerability profile.

MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing neutropenia, and thus facilitating its administration according to the time and doses as scheduled by the specialist.

AKYNZEO® (netupitant/palonosetron) is the first and only fixed-dose antiemetic in combining the new NK-1 antagonist netupitant with the sole antagonist of the second generation of serotonin, palonosetron, already marketed by Italfarmaco since 2006 as ALOXI®. Thanks to its totally innovative oral formulation and to the characteristics of its active ingredients, which act in a synergistic and long acting way, AKYNZEO® is able to ensure the highest levels of safety and efficacy in the prevention of nausea and vomiting, with a single dose ready to use, administered before cancer chemotherapy. AKYNZEO® so simplifies the management of antiemetic prophylaxis and facilitates better compliance with the recommendations of the major international guidelines on the prevention of nausea and vomiting from chemotherapy.

Zarelis: (Venlafaxine 37.5, 75, 150 and 225mg tablets) indicated in the treatment of major depressive episodes, prevention of recurrences of major depressive episodes, treatment of social anxiety disorder. The peculiar characteristics of Zarelis are the innovative formulation in osmotic sustained-release tablets and the possibility of administering the dose of 225 mg in a single tablet. This enables the simplification of treatment regimens and the reduction of total number of tables taken by the patient.